glp 1 anesthesia guidelines New Year, New Bod? Words of advice for Plastic Surgery patients on Ozempic ASA Advises No Longer Holding

Typical PA requirements include: Confirmed diagnosis of type 2 diabetes or obesity Documented BMI (often 30 or 27 with comorbidities) Failed trials of other medications Lifestyle modification attempts Recent A1C lab values (for diabetes) Documentation Must Include Height and weight with calculated BMI Diagnosis supporting medical necessity Treatment plan Follow-up and monitoring plan Compliance & Audit Risk GLP-1 medications are a high-risk audit target due to: Rapid growth in utilization High drug cost Off-label prescribing Weight-loss demand Common audit issues: Incorrect diagnosis codes Missing BMI documentation Lack of medical necessity Billing weight-loss drugs to Medicare Inappropriate use of unclassified J-codes Medicare Coverage Rules Medicare Part D generally does not cover weight-loss drugs , even if FDA-approved for obesity

Grape procyanidins B2 protect RPE cells against photooxidative damage

This would make it the third major incretin-based obesity drug to reach the market, following semaglutide (Wegovy) and tirzepatide (Zepbound), but the first to use the full triple-agonist mechanism

& Cota, D